Summary
- The Federal Trade Commission is taking legal action against pharmacy benefit managers for inflating the list price of insulin drugs.
- The action targets the “Big Three” PBMs: CVS Health’s Caremark Rx, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx.
- The FTC aims to address exploitative conduct that has led to skyrocketing insulin costs for patients who need it to survive.
- Advocates are hopeful that this initial action will lead to broader reform and increased competition in the pharmaceutical industry.